Loading clinical trials...
Loading clinical trials...
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Conditions
Interventions
Anti-OX40 Antibody PF-04518600
Avelumab
+4 more
Locations
12
United States
O'Neal Comprehensive Cancer Center
Birmingham, Alabama, United States
University of California, San Francisco
San Francisco, California, United States
Georgetown University
Washington D.C., District of Columbia, United States
University of Chicago Medicine Comprehensive Cancer Center
Evergreen Park, Illinois, United States
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Baltimore, Maryland, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
July 8, 2019
Primary Completion Date
January 31, 2027
Completion Date
January 31, 2027
Last Updated
April 17, 2026
NCT05422794
NCT04704661
NCT04550494
NCT05372640
NCT05673200
NCT06401889
Lead Sponsor
Laura Huppert, MD, BA
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions